Molecular Partners (MOLN) Leerink Global Healthcare Conference 2026 summary

Company overview and technology

• Focuses on mini-proteins called DARPins, engineered for high-affinity binding and multi-specificity.

• DARPins offer advantages of small size, stability, and tunable half-life, positioned between peptides and antibodies.

• Main activities are in radiotherapy (80%) and T cell engagers (20%), with radiotherapy prioritized for its attractive return on investment.

Radiotherapy strategy and isotope selection

• Adopts a vector approach, partnering for isotope supply and remaining flexible between lead and actinium isotopes.

• Agreements in place with Orano Med (lead) and Eckert & Ziegler (actinium), with commercial supply secured for lead.

• Isotope choice is tailored to each program, considering half-life and biodistribution; both isotopes may be tested clinically.

Compassionate care and early clinical insights

• Pioneered compassionate care programs, especially in South Africa, to rapidly de-risk and inform early development.

• First compassionate program for DLL3 (MP0712) provided valuable safety and efficacy insights, supporting phase I entry.